Barely Significant
← all excerpts

In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.

Mol Oncol · 2019 · PMC6487694 · PMID 30859681

1
hedged sentence
closest p
boldest claim

The sentences

a strong trendno p-value reported
Nevertheless, a strong trend for higher HIF‐1α expression levels was observed when comparing p53 nonfunctional/mutant cells versus p53 wild‐type cells after treatment with volasertib under hypoxic conditions ( P = 0.057). 3.2 Volasertib treatment results in mitotic arrest As Plk1 is a major regulator of mitotic cell division, the cell cycle distribution was investigated immediately after treatment with volasertib (0–20 n m , 24 h).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.